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S268 Poster Session IIabsolute neutrophil count of$500 cells/mm3 with.75%donor chi-
merism (RFLP confirmed). The dominating CBU was defined by
chimerism.75%. ALDHbr dosing was defined as high if the thawed
CBU delivered .47,000 ALDHbr cells/kg which was identified as
predictive of engraftment in single CBT in prior studies.
Results: The median patient age was 28.8 years (range, 3.7-64.8
years) and weight of 68.70 kg (range, 15.2-111.8 kg), 17 male, 13
CMV+. The median TNC per CBU was 2.2107/kg (range, 1.2-
10.3107/kg) with the median combined TNC of 3.9107/kg
(range, 2.7-18.0107/kg). 5 patients received two high ALDHbr
units, 10 patients received one high and one low ALDHbr unit,
and 12 received two low ALDHbr units. 23 patients were evaluable
for engraftment. 10 of 12 patients receiving $1 high ALDHbr
CBUs engrafted. The other 2 patients died of infection without en-
graftment (days 29 and 34 post-CBT). Conversely, 4 of 9 patients re-
ceiving low ALDHbr CBUs failed to engraft. In the high/low group,
only the high ALDHbr CBUs engrafted. The sensitivity and specific-
ity for ALDHbr dose is 0.71 and 0.67, respectively. The positive and
negative predictive values are 0.86 and 0.44, respectively. Other graft
parameters did not predict the dominating CBU.
Conclusion: Post-thaw ALDHbr dosing has a high positive predic-
tive value for predicting engraftment in dCBT. Further studies are
planned.
Table 1. ALDHbr Content of Units and Engraftment Status
ALDHbr Content of UnitsLow/Low High/Low High/HighTotal Patients 12 10 5
Evaluable Patients 9 9 5
Engrafted 5 7 [all with high unit] 5
Non-Engrafted 4 2297
COMPARATIVE EFFECTIVENESS ANALYSIS OF CD34 + SELECTED, T-CELL
DEPLETED (TCD) HLA-MATCHED SIBLING GRAFTS ON ALLOGENEIC HE-
MATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE
MYELOID LEUKEMIA (AML) IN COMPLETE REMISSION
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Numerous single institution studies have demonstrated that TCD
significantly reduces the incidence of graft-versus-host-disease
(GVHD). However, concerns about leukemia relapse, graft rejec-
tion, and variability in technique have limited the widespread appli-
cation of this approach. Promising results of TCD in patients with
AML prompted the Blood and Marrow Transplant Clinical Trials
Network (BMT CTN) to study a single uniform technique of CD
34+ selection using the Miltenyi CliniMacs device in a Phase II clin-
ical trial (BMT CTN 0303) of adult AML patients in first or second
complete remission (CR1/CR2) receiving peripheral blood stem cell
(PBSC), HLA-matched sibling donor transplants. We compared
outcomes of the 44 patients transplanted on the BMT CTN 0303
trial to a contemporary cohort of 102 patients with AML enrolled
on the BMT CTN 0101 – Phase III clinical trial of anti-fungal pro-
phylaxis after myeloablative HCTwith pharmacologic immune sup-
pression post-transplant (IST). This analysis compared TCD (BMT
CTN #0303) versus IST (BMTCTN 0101) with respect to the end-
points of: neutrophil engraftment (ENG), rates of acute and chronic
GVHD, transplant-related mortality (TRM), relapse, disease-free
survival (DFS), and overall survival (OS). Groups were similar for pa-
tient-, disease- and transplant specific characteristics except for the
proportion of patients in CR2 (TCD 7% vs. IST 27%), unfavorable
risk cytogenetics (TCD 32% vs. IST 18%), the use of mobilizedPBSC (TCD 100% vs. IST 81%) and graft composition (TCD #1
x105 CD3+ cells/kg). The results revealed lower rates of grades II-
IV acute (p5 0.046) and chronic GVHD (p5 0.01) in the TCD
group with no difference in ENG, leukemia relapse and TRM.
DFS and OS were similar between the two groups in the univariate
setting and also after adjustment for potential prognostic factors us-
ing a Cox proportional hazards model. Reduction of GVHD rates
without an increase in relapse rates and no requirement for post-
transplant immunosuppression are distinct advantages of this
method of TCD. These results support the extension of this ap-
proach to the unrelated donor setting and additional larger, prospec-
tive studies to definitively address the role of rigorous TCD inHCT.
TCD vs ISTOutcomes
TCD % (95% IST % (95%Outcome
Confidence Interval)
N5 44
Confidence
Interval) N5 102DFS at 6 mo 81 (66-90) 75 (68-87)
Relapse at 12 mo 19 (6-32) 19 (11-26)
TRM at 12 mo 19 (6-31) 22 (14-30)
ENG at 28 d 100 (86-100) 90 (79-100)
Acute GVHD II-IV at 100 d 20 (9-32) 37 (28-47)
Acute GVHD III-IV at 100 d 5 (0-11) 10 (4-16)
Chronic GVHD at 12 mo 19 (7-32) 47 (35-58)
Overall Survival at 12 mo 74 (57-85) 69 (59-77)298
PRECLINICAL EVALUATION OF HUMAN NOR-EPINEPHRINE TRANS-
PORTER (HNET)/MIBG REPORTER SYSTEM FOR IMAGING ADOPTIVELY
TRANSFERRED EBV-SPECIFIC CYTOTOXIC T-LYMPHOCITES
Doubrovin, M., Doubrovina, E., Moroz, M., Pankov, D., Wang, X.,
Olszewska,M., Riviere, I., O’Reilly, R., Larson, S., Blasberg, R.Memorial
Sloan-Kettering Cancer Center, New York, NY
Background:Wepreviously demonstrated hNET/MIBG to be a re-
porter gene system feasible for non-invasive quantitative monitoring
of cytotoxic T-cells (CTLs) in vivo. In this preclinical study, we test
whether the hNET reporter gene construct, under conditions simu-
lating adoptive immune cell therapy in patients, is potentially appli-
cable imaging paradigm.
Methods:The hNET reporter gene was cloned into a clinical grade
SFG pseudotypedMoMLV retroviral backbone, packaged in PG-13
retroviral producer cell line andwas used to transfect EBV-specificT
cells. Following the future clinical protocol, EBV-specific T cells
were pre-generated from a normal donor by stimulation with autol-
ogous EBV-transformed B-cells, as we previously described. Based
on expression of LNGFR, a selection gene in the same retroviral cas-
sette, reporter-gene expressing cells (CTL-NIN) were selected by
FACS sorting, characterized for cytotoxicity and frozen for long-
term storage. Initially, 123I-MIBG uptake was evaluated in the
CTL-NIN retrieved from liquid nitrogen storage according to
GMP requirements. In the preclinical study, upon thawing, prior
to adoptive transfer, CTLs were preincubated with 100 microCi/
ml (3.73 MBq/ml) of 124I-MIBG for 2 hours and injected into the
EBV-BLCL xenograft tumor model bearing NOD-SCID mice. As-
sessment MIBG radioactivity in CTL-NIN prior to injection and
MicroPET imaging of the injected radiolabeled cells in a phantom
and in the animals, with post-mortem ex-vivo radioactivity measure-
ments were performed.
Results: CTL-NINs were produced according to GMP procedures
appeared to have .90% reporter gene expression post-sorting with
improved specificity to EBV-BLCL targets (35% with 10:1 E:T ra-
tio). Storage and thawing decreased their cytotoxicity (25%) and
123I-MIBG uptake (217 ml/g, compared to 330 ml/g pre-freezing).
124I-MIBG labeling of CTL-NIN T cells ex-vivo was sufficient for
in vivo imaging. In vivo microPET imaging confirmed our ability
to detect 105 124I-MIBG ex vivo prelabeled CTL-NIN distributed
in a 1 cm3 tumor volume.
Conclusions: 1) hNET transduced CTLs produced and prepared
for adoptive immune cell transfer according to a clinical protocol
Poster Session II S269that preserves their anti-EBV specificity and functionality, can be la-
beled with 124I-MIBG and imaged by PET; 2) conditions for cell
preparation following pre-transfer thawing requires further optimi-
zation for improving PET imaging sensitivity.299
SAFETY OFMICAFUNGIN IN NEUTROPENIC PATIENTS INCLUDING THOSE
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Polyenes and azoles have potentially deleterious drug interactions
that can lead to important renal and hepatic toxicities in HCT recip-
ients. The echinocandins may offer safety advantages in such pa-
tients. In this analysis using data from 8 clinical development
studies, we examined renal and hepatic parameters in 588 neutro-
penic patients who received micafungin for prophylaxis of fungal in-
fections (n5 375), treatment for invasive candidiasis/candidemia
(IC/C; n5 120), or treatment for invasive aspergillosis (IA,
n5 93). The renal and hepatic function laboratory parameters for
the 3 indications are shown in Table 1; changes in laboratory param-
eters were calculated for each indication and, for the prophylaxis pa-
tients, for type of HCT. The proportion of patients with an increase
in creatinine from\2*ULN at baseline to$2*ULN at EOT and an
increase in bilirubin and ALT\2.5*ULN at baseline to$2.5*ULN
were provided by indication. Overall, the changes in hepatic and re-
nal function laboratory parameters were consistent with the underly-
ing conditions of the patients, and HCT patients did not appear to
experience greater increases in levels of creatinine, bilirubin, and
ALT compared to patients in the other groups.Description of laboratory parameters in micafungin neutropenic pa
Parameter
All patients
(n5 588)
All prophylaxis
patients
(n5 375)
Proph
non
pat
(n5
Days of micafungin, median 17.5 18.0 6.0
Creatinine (mg/dl),
median (min-max)
Baseline 0.70 (0.1-6.6) 0.6 (0.1-5.4) 0.40 (
Peak 0.86 (0.3-2.2) 0.70 (0.1-4.4) 0.70 (
EOT 0.71 (0.1-6.9) 0.70 (0.1-4.4) 0.40 (
Increase from\2 ULN at
baseline to $2 ULN at EOT, n/N (%)
16/527 (3.0) 1/363 (0.3) —
Bilirubin (mg/dl),
median, (min-max)
Baseline 0.80 (0-17.2) 0.70 (0.0-7.3) 0.80 (
Peak 1.10 (0.2-23.5) 1.10 (0.4-23.5) 0.80 (
EOT 0.80 (0.1-37.9) 0.70 (0.1-31.3) 0.60 (
Increase from\2.5 ULN at
baseline to $2.5 ULN at
EOT, n/N (%)
39/490 (8.0) 17/355 (4.8) —
ALT (U/L), median, (min-max)
Baseline 27.0 (2-655) 26.5 (4-472) 30.0 (
Peak 30.0 (1-2151) 39.0 (7-389) 44.0 (
EOT 25.0 (1-2793) 24.0 (1-2793) 27.0 (
Increase from\2.5 ULN
at baseline to $2.5 ULN
at EOT, n/N (%)
35/455 (7.7) 17/315 (5.4) —
ALT5Alanine aminotransferase; EOT5end of treatment; IA5 invasive aspe
normal.
*Comprised of 89 non-HCT patients, 16 autologous HCT patients, and 5 alloge
not available for these subgroups.
†Comprised of 57 non-HCT patients, 5 autologous HCT patients, and 31 alloge
not available for these subgroups.300
SUCCESS WITH A SHORTER COURSE PREEMPTIVE TREATMENT FOR CY-
TOMEGALOVIRUS (CMV) REACTIVATION AFTER MYELOABLATIVE HLA
MATCHED SIBLING DONOR HEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
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Johnston, L.2, Brown, J.1,2 1Stanford University Medical Center, Stan-
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The optimal duration of preemptive treatment of CMV reactiva-
tion following HCT is unclear. We analyzed 355 evaluable patients
(pts) who underwent myeloablative HCT from an HLA matched
sibling donor at Stanford University Medical Center between 1996
and 2008. Either donor or recipient was seropositive for CMV at
the time of transplant for 287 (79%) pts. Median follow up time
was 3.8 years (0.3-10.4). Patients were screened weekly for reactiva-
tion in plasma using a qualitative (1996-2000) or quantitative PCR
CMV test (2001-2008) (Amplicor, Roche Molecular Diagnostics)
through day 100 post-HCT. CMV viremia was detected in 127
(44%) of the 287 pts. Any positive result prompted pre-emptive
treatment with ganciclovir at 5 mg/kg IV twice daily for two weeks
and a concurrent investigation for signs or symptoms suggestive of
CMV disease. For patients without evidence of CMV disease in
whom CMV viremia resolved during the first three weeks, ganciclo-
vir was administered at 5 mg/kg daily for an additional week. In pa-
tients with CMV disease or in whom viremia persisted, daily
ganciclovir was administered for an additional 4 weeks. There
were no substantial differences between groups with respect to sex,
age, race, or underlying disease. The relative paucity of CMV reac-
tivation in the D+/R– group is predicted by previously published ob-
servations. Pts who successfully resolved CMV viremia with the
administration of only 3 weeks of ganciclovir were less likely (1) to
have received a preparative regimen containing TBI, (2) more likely
to have a lower initial CMV load as compared with patients whomet
criteria for 6week treatment. However, no difference between the
groups was noted regarding GVHD or treatment with steroids at
the time of initial viremia. Our data supports the utility of a 3tients
ylaxis,
-HCT
ients
30)
Prophylaxis,
autologous
HCT patients
(n5 161)
Prophylaxis,
allogeneic
HCT patients
(n5 184)
IC/Candidemia
patients
(n5 120)*
IA patients
(n5 93)†
17.0 21.0 14.0 29.0
0.2-0.9) 0.70 (0.1-5.4) 0.60 (0.1-2.7) 0.98 (0.1-4.7) 0.90 (0.2-6.6)
0.7-0.7) 0.75 (0.5-0.8) 0.70 (0.2-2.3) 0.98 (0.1-4.7) 1.00 (0.2-3.8)
0.2-0.8) 0.70 (0.2-4.4) 0.70 (0.1-2.4) 0.91 (0.1-6.9) 1.00 (0.2-3.8)
— — 10/79 (12.7) 5/85 (5.9)
0.1-2.8) 0.60 (0-3.1) 0.70 (0.1-7.3) 1.20 (0.2-11.6) 1.10 (0.1-17.2)
0.1-2.8) 1.25 (0.5-4.4) 1.10 (0.4-23.5) 1.32 (0.1-9.3) 1.30 (0.1-37.9)
0.1-5.7) 0.60 (0.1-4.4) 0.90 (0.2-31.3) 1.17 (0.2-13.9) 1.30 (0.1-37.9)
— — 9/65 (13.8) 13/70(18.6)
13-129) 23.0 (4-370) 28.0 (4-472) 31.5 (7-204) 27.0 (2-655)
13-96) 26.0 (13-33) 46.0 (7-389) 57.0 (17-88) 34.0 (3-194)
8-167) 20.0 (4-383) 28.0 (1-2793) 30.0 (6-1119) 26.0 (3-313)
— — 8/68 (11.8) 10/72 (13.9)
rgillosis; IC/C5 invasive candidiasis/candidemia; ULN5 upper limits of
neic HCT patients. Renal and hepatic function laboratory parameter data
neic HCT patients. Renal and hepatic function laboratory parameter data
